# US 2021/0095352 A1 · Methods for detecting norovirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0095352 A1
- Document ID: US20210095352A1
- Status: Published application
- Kind: A1
- Application number: 17/063,078
- Filed: 2020-10-05
- Published: 2021-04-01
- Earliest claimed: 2016-06-03
- Assignees: Quest Diagnostics Investments Incorporated
- Applicants: Quest Diagnostics Investments LLC
- Inventors: Peter Lee; Raymond Huang; Kristin Ramos; Jules Chen; Michelle Tabb
- Web page: https://patentgrep.com/patent/US20210095352A1

## CPC

- C12Q 1/701: {Specific hybridization probes}
- A61P 31/14: for RNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12Q 1/68: involving nucleic acids
- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- G01N 33/56983: {Viruses}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2770/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- G01N 2333/08: RNA viruses
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides methods and compositions for determining whether a patient exhibiting acute gastroenteritis will benefit from treatment with therapeutic agents that inhibit Norovirus genogroup I (GI) or Norovirus genogroup II (GII). The methods disclosed herein are based on detecting Norovirus genogroup I (GI) and Norovirus genogroup II (GII) in a stool sample without extracting viral nucleic acids from a clinical specimen prior to performing real-time reverse transcription PCR. Kits for use in practicing the methods are also provided.

## Claims

### Claim at position 1

1-56. (canceled)

### Claim 57

A method for detecting the presence of Norovirus genogroup I (GI) in a stool sample comprising: contacting the stool sample with a primer pair that amplifies a Norovirus genogroup I (GI) target nucleic acid comprising nucleotides that are at least 80-95% identical to SEQ ID NO: 2 or a complement thereof, to produce a reaction-sample mixture under conditions where real-time RT-PCR amplification of the Norovirus genogroup I (GI) target nucleic acid, if present in the stool sample, occurs without extraction of target nucleic acids from the stool sample.

### Claim 58 (depends on 57)

The method of claim 57, further comprising:
(a) subjecting the reaction-sample mixture to real-time RT-PCR conditions under which the Norovirus genogroup I (GI) target nucleic acid present in the stool sample is amplified to produce a fluorescent signal;
(b) detecting the fluorescent signal generated by each amplified Norovirus genogroup I (GI) target nucleic acid produced in step (a); and
(c) detecting the presence of Norovirus genogroup I (GI) in the stool sample by evaluating the fluorescent signal of each amplified Norovirus genogroup I (GI) target nucleic acid;
wherein the stool sample is not subjected to an extraction or purification step prior to amplification.

### Claim 59 (depends on 57)

The method of claim 57, wherein the primer pair consists of a forward primer comprising 5′d CGYTGGATGCGITTYCATGA 3′(SEQ ID NO: 5) and a reverse primer comprising 5′d TCCTTAGACGCCATCATCATTTAC 3′ (SEQ ID NO: 6).

### Claim 60 (depends on 57)

The method of claim 57, wherein Norovirus genogroup I (GI) comprises one or more genotypes selected from the group consisting of GI.1, GI.2, GI.3, GI.4, GI.5, GI.6, GI.7, GI.8, GI.9, GI.10 and GI.14.

### Claim 61 (depends on 57)

The method of claim 57, further comprising contacting the stool sample with a first nucleic acid probe that is capable of specifically hybridizing to a segment of the Norovirus genogroup I (GI) target nucleic acid sequence of SEQ ID NO: 2 or a complement thereof, wherein the first nucleic acid probe is detectably labeled and comprises 5′d TGGACAGGAGAYCGCIATCTCYTGCCCGA 3′ (SEQ ID NO: 7) or a complement thereof.

### Claim 62 (depends on 61)

The method of claim 61, wherein the first nucleic acid probe is detectably labelled with CFR610 fluorophore.

### Claim 63 (depends on 57)

The method of claim 57, further comprising contacting the stool sample with a second nucleic acid probe that is capable of specifically hybridizing to a segment of the Norovirus genogroup I (GI) target nucleic acid sequence of SEQ ID NO: 2 or a complement thereof, wherein the second nucleic acid probe is detectably labeled and comprises 5′d TGGACAGGAGATCGCAATCTACTGCCTGA 3′(SEQ ID NO: 8) or a complement thereof.

### Claim 64 (depends on 63)

The method of claim 63, wherein the second nucleic acid probe is detectably labelled with CFR610 fluorophore.

### Claim 65

A method for detecting the presence of Norovirus genogroup II (GII) in a stool sample comprising: contacting the stool sample with a primer pair that amplifies a Norovirus genogroup II (GII) target nucleic acid comprising nucleotides that are at least 80-95% identical to SEQ ID NO: 4 or a complement thereof, to produce a reaction-sample mixture under conditions where real-time RT-PCR amplification of the Norovirus genogroup II (GII) target nucleic acids, if present in the stool sample, occurs without extraction of target nucleic acids from the stool sample.

### Claim 66 (depends on 65)

The method of claim 65, further comprising:
(a) subjecting the reaction-sample mixture to real-time RT-PCR conditions under which the Norovirus genogroup II (GII) target nucleic acid present in the stool sample is amplified to produce a fluorescent signal;
(b) detecting the fluorescent signal generated by each amplified Norovirus genogroup II (GII) target nucleic acid produced in step (a); and
(c) detecting the presence of Norovirus genogroup II (GII) in the stool sample by evaluating the fluorescent signal of each amplified Norovirus genogroup II (GII) target nucleic acid;
wherein the stool sample is not subjected to an extraction or purification step prior to amplification.

### Claim 67

A method for selecting a patient suffering from acute gastroenteritis for treatment with a therapeutic agent that inhibits Norovirus genogroup II (GII) comprising: contacting a stool sample obtained from the patient with: contacting the stool sample with a primer pair that amplifies a Norovirus genogroup II (GII) target nucleic acid comprising nucleotides that are at least 80-95% identical to SEQ ID NO: 4 or a complement thereof, to produce a reaction-sample mixture under conditions where real-time RT-PCR amplification of the Norovirus genogroup II (GII) target nucleic acids, if present in the stool sample, occurs without extraction of target nucleic acids from the stool sample.

### Claim 68 (depends on 67)

The method of claim 67, further comprising:
(a) subjecting the reaction-sample mixture to real-time RT-PCR conditions under which the Norovirus genogroup II (GII) target nucleic acid present in the stool sample is amplified to produce a fluorescent signal;
(b) detecting the fluorescent signal generated by each amplified Norovirus genogroup II (GII) target nucleic acid produced in step (a); and
(c) selecting the patient for treatment with a therapeutic agent that inhibits Norovirus genogroup II (GII), if a fluorescent signal for the Norovirus genogroup II (GII) target nucleic acid is detected;
wherein the stool sample is not subjected to an extraction or purification step prior to amplification.

### Claim 69 (depends on 65, 67)

The method of claim 65 or 67, wherein the primer pair consists of a forward primer comprising 5′d TGTTYAGGTGGATGAGRTTCTCIGA 3′ (SEQ ID NO: 9) and a reverse primer comprising 5′d TCGACGCCATCTTCATTCACA 3′ (SEQ ID NO: 10).

### Claim 70 (depends on 65, 67)

The method of claim 65 or 67, wherein Norovirus genogroup II (GII) comprises one or more genotypes selected from the group consisting of GII.1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII.8, GII.9, GII.10, GII.11, GII.12, GII.13, GII.14, GII.15, GII.16, GII.17, GII.18, GII.19, GII.20, GII.21, GII.22, and GII.23.

### Claim 71 (depends on 65, 67)

The method of claim 65 or 67, further comprising contacting the stool sample with a nucleic acid probe that is capable of specifically hybridizing to a segment of the Norovirus genogroup II (GII) target nucleic acid sequence of SEQ ID NO: 4 or a complement thereof, wherein the nucleic acid probe is detectably labeled and comprises 5′d ACGTGGGAGGGCGATCGCAATCT 3′ (SEQ ID NO: 11) or a complement thereof.

### Claim 72 (depends on 71)

The method of claim 71, wherein the nucleic acid probe is detectably labelled with FAM fluorophore.

### Claim 73 (depends on 57, 65)

The method of claim 57 or 65, further comprising contacting the stool sample with a control primer pair that amplifies a control target nucleic acid of SEQ ID NO: 12 or a complement thereof.

### Claim 74 (depends on 73)

The method of claim 73, wherein the control primer pair consists of a forward primer comprising 5′d CTCGTCGACAATGGCGGAA 3′ (SEQ ID NO: 13) and a reverse primer comprising 5′d TTCAGCGACCCCGTTAGC 3′ (SEQ ID NO: 14).

### Claim 75 (depends on 73)

The method of claim 73, further comprising contacting the stool sample with a control nucleic acid probe that specifically hybridizes to a segment of the control target nucleic acid or a complement thereof, wherein the control nucleic acid probe is detectably labeled and comprises 5′d GCTTGGGGCGACAGTCACGTCGC 3′ (SEQ ID NO: 15) or a complement thereof.

### Claim 76 (depends on 75)

The method of claim 75, wherein the control nucleic acid probe is detectably labelled with Q670 fluorophore.

### Claim 77 (depends on 57, 65)

The method of claim 57 or 65, wherein real-time RT-PCR amplification is performed in a direct amplification disc in concert with an integrated thermal cycler.

### Claim 78 (depends on 57, 65)

The method of claim 57 or 65, wherein the stool sample comprises unformed stool, formed stool, or a rectal swab stored in liquid Amies media.
